Vicore Pharma Holding AB (VCRE)

Vicore Pharma Holding AB is a clinical-stage pharmaceutical company based in Gothenburg, Sweden, focused on developing treatments for idiopathic pulmonary fibrosis and other serious lung diseases. Its American Depositary Shares trade on Nasdaq, and its ordinary shares are also listed on Nasdaq Stockholm.

The company's lead candidate is buloxibutid, an oral small molecule that stimulates the angiotensin II type 2 receptor, a pathway thought to help protect and repair lung tissue and counteract fibrosis. Vicore is advancing buloxibutid in clinical trials in idiopathic pulmonary fibrosis.

Vicore also works on other molecules targeting the angiotensin II type 2 receptor for potential use in fibrotic and related diseases.